Logo IZB Innovations- und Gründerzentrum Biotechnologie
IZB Signet

Biotech report by vfa: Biopharmaceuticals successfully gain market share

In 2022, more than half of the newly approved drugs in Germany were biopharmaceuticals.
May 2023
Titelseite Biotech Report
Cover page of the "Biotech-Report Kompakt" – Medical Biotechnology in Germany 2023. Biopharmaceuticals: Key economic figures for Germany as a biotech location.
“The results underline the outstanding relevance of biotechnology for healthcare in Germany. This is only possible due to strong-performing companies. They are enormously research- as well as development-focused and thus make an important contribution to Germany’s innovative strength.”
Han Steutel, President of vfa

© vfa.

menuchevron-down
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.